



Jean-Jacques Bienaimé

Genencor International (Palo Alto, CA) has announced the appointment of **Jean-Jacques Bienaimé** as chief executive officer and president. He succeeds **W. Thomas Mitchell**, who will continue as chairman of the board. Mr. Bienaimé comes

to Genencor from SangStat, where he was chairman, president, and CEO. He is currently a member of the board of directors of Aerogen, Stem Cell Inc., and the Fox Chase Cancer Center in Philadelphia.

La Jolla Pharmaceutical (LJP; San Diego, CA) has appointed **David Duncan, Jr.** to the position of chief financial officer and **Karen Church** to the position of vice president of regulatory affairs. Mr. Duncan has served as CFO at Medinox, Tanox, Neuromedical Systems, and Telios Pharmaceuticals. Ms. Church has held regulatory positions with Ancile Pharmaceuticals, Gensia (now Sicor), Neurocrine Biosciences, InSite Vision, Roche, Abbott, and Astra. Additionally, LJP announced the promotions of **Matthew D. Linnik** from executive vice president of research to chief scientific officer and executive vice president of research and **William J. Welch** from vice president of marketing to vice president of sales and marketing.

British Biotech (London) has announced the resignation of **Elliot Goldstein** from his position as CEO and from the board of the company. A search for a replacement has been initiated and **Tim Edwards**, currently chief operating officer, has been appointed acting CEO.

Wayne R. Gombotz has been named vice president, process sciences and pharmaceutical development, at Corixa (Seattle, WA). Most recently, he served as senior director, analytical chemistry and formulation at Immunex, where he played a major role in the development and launch of its rheumatoid arthritis drug Enbrel.

GenoMed (St. Louis, MO) has named **Paula Hempen** as its chief scientific officer. Dr. Hempen has spent the last three years in the laboratory of Scott Kern at the Sydney Kimmel Comprehensive Cancer Center at Johns Hopkins University.

Cellegy Pharmaceuticals (S. San Francisco, CA) has named **David A. Karlin** to the position of vice president, clinical research. Dr. Karlin previously served in senior clinical development positions at several biotechnology companies, including

Generic, Matrix Pharmaceutical, and SciClone Pharmaceuticals.

William P. Keane has been appointed vice president and chief financial officer at Genta (Berkeley Heights, NJ). Most recently, he served as vice president of sourcing, strategy, and operations effectiveness at Bristol Myers Squibb. From 2000 to 2001, he served as CFO of Covance Biotechnology Services.

Arena Pharmaceuticals (San Diego, CA) has announced the appointments of **J. Clayburn La Force, Jr.** and **Duke K. Bristow** to the company's board of directors. They fill the vacancies created by the resignations of **John P. McAlister III** and **Michael Steinmetz** in October. Dr. La Force previously served as chairman of the UCLA Economics Department and Dean of the Anderson School at UCLA. He is currently a member of six boards of directors. Dr. Bristow, an economist, is responsible for a corporate governance program in the Harold Price Center for Entrepreneurial Studies at the Anderson Graduate School of Management at UCLA. Dr. Bristow worked for ten years at Eli Lilly & Co., holding various positions in financial management, controllership and pharmaceutical marketing and licensing.



John Padfield has been named non-executive chairman of the board of directors of Lorantis (Cambridge, UK). Dr. Padfield has been CEO of Amersham Health and an executive board member of Amersham plc, its parent company, since 1999. He was previously CEO of Chiroscience.

Tularik (S. San Francisco, CA) has announced that **Andrew J. Perlman** has rejoined the company as executive vice president. Dr. Perlman was a member of Tularik's management team for nearly ten years, serving initially as vice president of medical research and corporate development and later as executive vice president. He returns to Tularik from Affymax, where he served as CEO.

Medicinal chemistry start-up Kemia (San Diego, CA) has appointed **Edward Roberts** chief scientific officer and **Jan Lundstrom** vice president of biology. Before joining Kemia, Dr. Roberts was senior vice president and head of discovery chemistry for F. Hoffman-La Roche, with overall responsibility for drug discovery chemistry done in the vascular, metabolic and CNS therapeutic areas. Dr. Lundstrom most recently headed AstraZeneca's pharmacokinetic program and has 27 years of experience in preclinical drug development.